Fig. 5
From: Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor
TS suppressed the development of TNBC in vivo. The images of bioluminescence of TNBC implanted in xenograft mice of MDA-MB-231luc, from 0 to the 35th day of treatment, were displayed (TS was given at 45 mg/kg body weight to mice once every 2 days orally) (A). At 14th day, the bioluminescence value in TS group ((2.93 ± 0.8)×107) was significantly lower than that of NC ((5.65 ± 0.96) ×107, P < 0.05), and this trend remained till the 35th day of treatment (B). The inhibition rate was 5.17 ± 13.11% at 7th day, and gradually climbed to 75.53 ± 14.45% at 35th day of treatment (C). As for survival assay, mice in TS group were all alive by the end of the 50th day of treatment, and mice of NC group all died before 48th day of treatment (log-rank P = 0.007) (D)